

Supplemental Information Disclosure Statement:

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants direct the Examiner's attention to the following documents listed below, certain of which are also listed on Form PTO-1449 (**Exhibit A**).

This Supplemental Information Disclosure Statement is being submitted pursuant to 37 C.F.R. §1.97(b)(3) before the mailing of a first Office Action on the merits. Thus, this Supplemental Information Disclosure Statement should be entered and considered.

In accordance with 37 C.F.R. §1.92(a)(2)(ii), copies of U.S. Patent Application Publications listed herein are not provided. Accordingly, copies of documents listed below as items 1 and 2 are not submitted herewith. Copies of documents listed below as items 3-21 are attached hereto as **Exhibits 1-19**.

1. U.S. Application Publication No. US 2006-0094049, published May 4, 2006;
2. U.S. Application Publication No. US 2006-0051373, published March 9, 2006;
3. PCT International Application Publication No. WO 2006/002079, published January 5, 2006 (**Exhibit 1**);
4. Binley, J.M. et al. (2002) "Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins." J. of Virology, Vol 76 No. 6 pages 2606-2616 (**Exhibit 2**);

5. Chen, S. (1993) "Mutational Analysis Of The Leucine Zipper-Like Motif Of The Human Immunodeficiency Virus Type 1 Envelope Transmembrane Glycoprotein." J. of Virology 67 (6):3615-3619 (**Exhibit 3**);
6. Creson J. (1999) "The Mode and Duration of Anti-CD28 Costimulation Determine Resistance to Infection by Macrophage-Tropic Strains of Human Immunodeficiency Virus Type 1 in Vitro. Journal of Virology, Nov. 1999, Vol. 73, No.11, p. 9337-9347 (**Exhibit 4**);
7. Ditzel H J et al. (1997) "Mapping The Protein Surface Of Human Immunodeficiency Virus Type 1 gp 120 Using Human Monoclonal Antibodies From Phage Display Libraries" J. of Molecular Biology, 267 (3):684-695 (**Exhibit 5**);
8. Haynes, B.F. (1996) "Update on the Issues of HIV Vaccine Development" Ann. Med. 28:39-41 (**Exhibit 6**);
9. Nakashe, J. et al., (2001) "Rectal immunization with antigen-containing microspheres induces stronger Th2 responses than oral immunization: a new method for vaccination" Vaccine, Butterworth Scientific Guildford, GB, Vol. 20, no. 3-4, pages 377-384 (**Exhibit 7**);
10. Parker, Carole, et al. (2001) "Fine Definition of the Epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5" J. of Virol. Vol. 75, No. 22, pages 10906-10911 (**Exhibit 8**);
11. Sanders R. et al., (2002) "Stabilization Of The Soluble, Cleaved, Trimeric Form Of The Envelope Glycoprotein Complex

Of Human Immunodeficiency Virus Type 1" Journal of Virology, 76 (17):8875-8889 (**Exhibit 9**);


12. Sanders R. (2000) "Variable-Loop-Deleted Variants of the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Can Be Stabilized by an Intermolecular Disulfide Bond between the gp120 and gp41 Subunits" Journal of Virology, June 2000, Vol. 74, No. 11, p.5091-5100 (**Exhibit 10**);
13. Schulke et al. (2002) "Oligomeric And Conformational Properties Of A Proteolytically Mature, Disulfide-Stabilized Human Immunodeficiency Virus Type 1 gp140 Envelope Glycoprotein" J. of Virology, 76 (15):7760-7776 (**Exhibit 11**);
14. April 15, 2004 International Search Report in connection with International Application No. PCT/US02/28331 (**Exhibit 12**);
15. May 12, 2004 International Search Report in connection with International Application No. PCT/US02/28332 (**Exhibit 13**);
16. August 22, 2006 Supplementary European Search Report for Application No. EP 02 77 0472 (**Exhibit 14**);
17. September 7, 2000 International Search Report in connection with Application No. PCT/US00/17267 (**Exhibit 15**);
18. January 23, 2002 International Preliminary Examination Report in connection with International Application No. PCT/US00/17267 (**Exhibit 16**);
19. March 5, 2003 Supplementary European Search Report in

connection with Application No. EP/00944801 (**Exhibit 17**);


20. June 11, 2003 Supplementary European Search Report for App. No. EP/00944801 (**Exhibit 18**) and
21. August 31, 2006 Supplementary European Search Report for Application No. EP/02770473 (**Exhibit 19**).

No fee, except the \$60.00 fee for a one-month extension of time, is deemed necessary in connection with the filing of this Communication. However, if any additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham, LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
 John P. White Reg. No. 28,678	12/5/06 Date

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Application Number	10/780,993
	Filing Date	February 18, 2004
	First Named Inventor	James M. Binley et al.
	Art Unit	
	Examiner Name	
	Attorney Docket No.	59331-AA

U.S. PATENT DOCUMENTS

Examiner Initials [*]	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		U.S. 2006-0094049	05-04-2006	
		U.S. 2006-0051373	03-09-2006	

FOREIGN PATENT DOCUMENTS

Examiner Initials [*]	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T ⁶
		WO 2006/002079	01-05-2006		

EXAMINER SIGNATURE	DATE CONSIDERED
---------------------------	------------------------

***EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds of Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

Applicants: James M. Binley et al.
 Serial No.: 10/780,993
 Filed: February 18, 2004
 Exhibit A

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Application Number	10/780,993
	Filing Date	February 18, 2004
	First Named Inventor	James M. Binley et al.
	Art Unit	
	Examiner Name	
	Attorney Docket No.	59331-AA

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Binley, J.M. et al. (2002) "Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins." J. of Virology, Vol 76 No. 6 pages 2606-2616	
		Chen, S. (1993) "Mutational analysis of the leucine zipper-like motif of the human immunodeficiency virus type 1 envelope transmembrane glycoprotein" J. of Virology, June 1993, Vol. 67, No. 6, p. 3615-3619	
		Creson J. (1999) "The Mode and Duration of Anti-CD28 Costimulation Determine Resistance to Infection by Macrophage- Tropic Strains of Human Immunodeficiency Virus Type 1 in Vitro" Journal of Virology, Nov. 1999, Vol. 73, No.11, p. 9337-9347	
		Ditzel H J et al. (1997) "Mapping the protein surface of human immunodeficiency virus type 1 gp 120 using human monoclonal antibodies from phage display libraries" J. of Molecular Biology, Vol. 267 No. 3, pages 684-695	
		Haynes, B.F. (1996) "Update on the Issues of HIV Vaccine Development" Ann. Med. 28:39-41	
		Nakashe, J. et al., (2001) "Rectal immunization with antigen-containing microspheres induces stronger Th2 responses than oral immunization: a new method for vaccination" Vaccine, Butterworth Scientific Guildford, GB, Vol. 20, no. 3-4, pages 377-384	
		Parker, Carole, et al. (2001) "Fine Definition of the Epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5" J. of Virol. Vol. 75, No. 22, pages 10906-10911	
		Sanders R. et al., (2002) "Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1." Journal of Virology, Vol. 76, No. 17, p.8875-8889	
		Sanders R. (2000) "Variable-Loop-Deleted Variants of the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Can Be Stabilized by an Intermolecular Disulfide Bond between the gp120 and gp41 Subunits" Journal of Virology, June 2000, Vol. 74, No. 11, p.5091-5100	
		Schulke, Norber et al. (2002) "Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein." J. of Virology, Vol 76 No. 15 pages 7760-7776	

EXAMINER
SIGNATURE

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a checkmark here if English language Translation is attached.